DPP4 and atrial fibrillation: Patients using dipeptidyl peptidase-4 (DPP-4) inhibitors as a second-line therapy after metformin had a lower risk of new-onset AF compared to those using non-DPP-4 diabetes drugs as a second-line treatment [268].